Salubris BioMedical Secures Hundreds of Millions in Series A Strategic Financing to Advance Cardiovascular and Cerebrovascular Innovation Pipeline

VCBeat learned that Salubris Medtech, a wholly-owned subsidiary of Salubris Pharmaceuticals (002294.SZ), has recently completed a Series A strategic financing round worth several hundred million yuan. The round was led by Cinda Kunpeng (Shenzhen) Equity Investment Management Co., Ltd. (hereinafter referred to as Cinda Kunpeng), with Hery Capital serving as the exclusive financial advisor. The proceeds from this financing will mainly be used to advance the clinical progress of the existing cardiovascular and cerebrovascular product pipeline and to replenish working capital.

Salubris Medtech is an innovative cardiovascular medical device platform under Salubris Pharmaceuticals. The company has developed multiple globally and China-first vascular implantation and interventional devices through self-research, acquisitions, and product rights introductions in areas such as neurointervention, cardiovascular intervention, peripheral vascular diseases, structural heart diseases, electrophysiology, and hypertension. It aims to create comprehensive solutions spanning diagnosis, prevention, treatment, and rehabilitation for the aforementioned cardiovascular conditions. The company has successfully acquired and integrated Suzhou Hengchen Medical, Beijing Yalun Biotech, and Shenzhen Keyitong Biotech; invested in and obtained core product rights from Switzerland's Med Alliance and the U.S.-based Mercator; and strategically invested in Jinshi Biotech, Sichuan Jinjiang Electronics, and Shanghai Yueguang Medical, accumulating extensive in-house R&D and external product development and commercialization capabilities as a mature medical device platform.

The core products of the company include the Maurora vertebral artery stent in the field of neurointervention, which is the world's first rapamycin drug-eluting stent for vertebral artery stenosis. It received NMPA approval at the end of 2020 and achieved remarkable commercial milestones in 2021. In cardiovascular intervention, the rapamycin coronary drug-coated balloon, which features globally leading drug-coating technology, is currently in the registration clinical stage and is expected to become one of the first rapamycin drug-coated balloons to be marketed in China. The LAMax LAAC left atrial appendage occluder for structural heart disease is the earliest domestically produced device in China and is among the most widely used globally, similar to Boston Scientific’s WATCHMAN.^™The left atrial appendage closure device product, which has undergone randomized controlled trials, has now entered the registration application stage. In the direction of peripheral vascular devices, multiple innovative products have been strategically developed, including inferior vena cava filters, iliac vein stents, drug-eluting stents for lower limbs, and sirolimus-coated peripheral drug balloons. In the coming years, the company will continue to increase its investment in innovation, expand its product pipeline, and enhance its commercialized product portfolio.

At the same time, the company has completed the integration of clinical operation resources, the construction of a centralized production base, and the establishment of a sales platform with in-depth coverage across China. The company will always adhere to starting from clinical needs, centering on patients, promoting evidence-based medicine, advancing independent innovation R&D alongside the introduction of global innovative technologies, forming a pharmaceutical and device strategic synergy with Salubris Medtech, and is committed to becoming a globally integrated innovative cardiovascular and cerebrovascular medical device platform enterprise encompassing R&D, clinical, production, and commercialization.

Ye Yuxiang, General Manager of Salubris Pharma and Chairman of Salubris MedtechMr.Salubris Medtech stated that its mission is to provide excellent pharmaceutical products for human health. We are committed to becoming China's most influential innovative enterprise in the internationalization of high-end prescription drugs and biomedicine. After more than two decades of dedicated efforts, Salubris Group has become a leading listed pharmaceutical company in the field of cardiovascular and cerebrovascular disease treatment, accumulating rich platform operation experience and resources in this track. Rooted in this fertile ground, Salubris Medtech aims to build a world-class medical device giant relying on the group's resources. After years of hard work and investing billions of self-owned funds, the keel of this "aircraft carrier" has been completed, marking the official start of Salubris Medtech Platform 2.0 era. We are pleased that our perspectives and practices have been recognized by outstanding investment institutions and investment banking partners such as Cinda Kunpeng and Haoyue Capital. We believe that all past achievements are just preludes. The Salubris Medtech platform has set sail, heading towards the deep sea, the future, and success.

Mr. Zhao Yanchen, Executive Vice General Manager of Salubris MedtechSalubris, as a leading innovation-driven pharmaceutical company in China focusing on the cardiovascular and cerebrovascular fields, has built a relatively scarce medical device platform in China—Salubris Medtech—through acquisitions, investments, and self-research. Covering several important细分fields such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, and electrophysiology, Salubris Medtech fully leverages the pharmaceutical-device synergy advantages of the Salubris system in product differentiation, R&D, production, sales, and internationalization. Against the backdrop of healthcare industry reform in China, Xinda Kunpeng and Salubris have joined hands to empower the industry with finance and support the development of the real economy. They aim to build Salubris Medtech into a leading global innovative medical device platform enterprise in China, addressing unmet clinical needs and providing better comprehensive solutions for a wide range of patients.

Mr. Liu Hao, Founder and Chief Executive Officer of Haoyue CapitalSalubris Medtech, as a leading platform enterprise in China, has accumulated extensive industry and technical expertise over the years, poised for significant growth. Under the leadership of CEO Ye and an excellent management team, the company has deeply integrated into the industry through self-research, acquisitions, investments, and other diversified methods. It has completed several cycles from product development, certification to commercialization, providing more comprehensive solutions for disease treatment, and gaining high recognition from industry experts. We firmly believe that in the future, various segments of China's medical device industry will become a competitive arena for large platforms, with the industry gradually moving towards consolidation. Salubris Medtech’s strong integration and industrialization capabilities have been refined and validated over the years, integrating advanced global technologies, absorbing, digesting, and innovatively applying them. We are highly anticipating that in the next 5-10 years, the company will build a carrier-grade pharmaceuticals and devices ecosystem in the cardiovascular and cerebrovascular fields, driving industry development.

Shenzhen Salubris Pharmaceuticals Co., Ltd. was established in 1998 and listed on the Shenzhen Stock Exchange in 2009 (Stock Code: 002294). It is an innovation-driven pharmaceutical company based in China with a global presence. The company has set up multiple research and development centers in China and the United States, covering the entire industry chain and accessing global innovative resources to study disease mechanisms, explore treatment methods, and develop innovative drugs. Salubris adheres to the value of "patient-centeredness" to meet unmet clinical needs. Focusing on the cardiovascular and cerebrovascular fields, it has formed a strategically synergistic product system of chemical drugs, biologics, and medical devices to provide comprehensive solutions for patients. It explores innovative drugs in areas such as blood glucose reduction, anti-tumor, orthopedics, nephrology, and anti-infection, building an original drug innovation system.

Xinda Kunpeng, established in April 2019, is an investment management institution specializing in the field of corporate mergers and acquisitions. It focuses on strategic emerging industries in the Guangdong-Hong Kong-Macao Greater Bay Area, creating value by empowering industries. Xinda Kunpeng has initiated a merger and acquisition fund with a scale of 3 billion RMB, mainly engaging in merger and acquisition activities related to listed companies. The fund provides essential development capital for enterprises and facilitates cooperation in acquiring high-quality assets within the industry. This merger and acquisition fund will primarily invest in strategic emerging industries encouraged by the state, including advanced manufacturing, healthcare, and next-generation information technology, with the mission of promoting the transformation and upgrading of the real economy. It aims to assist in the industrial structure upgrade of the Guangdong-Hong Kong-Macao Greater Bay Area, including Shenzhen, to create and enhance investment value. Through collaboration with industry partners, resource integration, and specialized division of labor, it seeks to achieve a win-win situation for different participants in the industrial chain, thereby building a healthy ecosystem to promote the development of the real economy.

HaoYue Capital, founded in January 2014, is a leading investment bank in China that focuses on the healthcare industry. Headquartered in Shanghai, the company has regional offices in Beijing and Shenzhen. HaoYue Capital is committed to supporting China's outstanding healthcare companies in successfully accessing the capital markets through capital assistance and research-driven insights, creating added value for its clients. The partnership team consists of senior investment bankers with years of experience in China's healthcare sector, and the professional team comprises over 70 members. HaoYue Capital consistently tracks trends and market dynamics in healthcare investments, covering multiple sub-sectors such as biopharmaceuticals, innovative medical devices, IVD and life sciences, health services, and digital healthcare. In 2021, HaoYue Capital completed more than 50 private equity financing, M&A integration, and complex spin-off transactions involving listed companies, with a total transaction value of tens of billions of RMB, demonstrating comprehensive leadership across various subfields of the healthcare industry.